In one paragraphArticle in American journal of physiology. Endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Daniel E VieiraDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.ORCID 0009-0004-1080-6814 Emily M LangmeyerDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.
Marissa D CortopassiDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.
William B RubioDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.ORCID 0009-0006-1196-3752 Sarah N FlierDivision of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
Lynn BryMassachusetts Host-Microbiome Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
Alexander S BanksDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.ORCID 0000-0003-1787-6925 Funding
STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4MP&F programP30DK135043 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Dennis Brown · 2023 to 2026
$5.4MCalRepository: A database of indirect calorimetry experiments for the study of energy homeostasisR01DK133948 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BANKS, ALEXANDER · 2022 to 2025
$2.0MJoslin-BIDMC Postbac Program in Diabetes and MetabolismR25DK140752 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 2024 to 2026
$1.2MInstrumentation for Noninvasive Measurement of Glucose and Energy Balance in Mice with Continuous Glucose Telemetry and Indirect CalorimetryS10OD028635 · OD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BANKS, ALEXANDER · 2020 to 2020
$737kHHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK034854HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK135043HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK133948HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R25DK140752NIDDK NIH HHS P30 DK034854NIDDK NIH HHS P30 DK135043NIDDK NIH HHS R01 DK133948NIDDK NIH HHS R25 DK140752NIH HHS S10 OD028635
6 · The paper itselfAbstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are highly effective treatments for obesity and type 2 diabetes but are often associated with gastrointestinal side effects including delayed transit times through the gastrointestinal tract. We present a noninvasive breath test to measure oral-cecal transit time (OCTT) in mice that could be readily translated to clinical studies. Current methods for measuring OCTT are limited by invasiveness, terminal procedures, anesthesia, radioactive tracers, or stress-induced influence on the outcomes. Here we demonstrate that
Indexed as
CecumGastrointestinal TransitGlucagon-Like PeptidesHypoglycemic AgentsMannitolAnimalsBreath TestsCalorimetry, IndirectCarbon IsotopesMaleMiceMice, Inbred C57BLSemaglutideCarbon-13Carbon IsotopesGlucagon-Like PeptidesHypoglycemic AgentsMannitolSemaglutideGLP-1 receptor agonistgut microbiotaindirect calorimetryoral-cecal transit timestable isotope breath test
Identifiers
PMID42623313
PMCPMC13615566
What OpenQuestion holds
Textmetadata
Read underepoch 390